Literature DB >> 1612036

Extracorporeal piezoelectric lithotripsy for retained bile duct stones.

J Weber1, H E Adamek, J F Riemann.   

Abstract

Extracorporeal piezoelectric shock wave lithotripsy (EPL) was performed in 35 patients with endoscopically non-extractable stones. With this lithotripter, stones are visualized by ultrasound and shock waves are produced by a piezoelectric acoustic generator. The stones could be localized in 32 out of 35 patients. Fragmentation was achieved in 91.4% and complete stone removal in 77.1%. These results show that piezoelectric lithotripsy is also a useful method for the treatment of complicated bile duct stones, as already demonstrated for the electrohydraulically and electromagnetically generated shock waves systems. The piezoelectric system is especially useful in elderly and frail patients because no general anesthesia is needed and only 14% of cases require analgesia or sedation.

Entities:  

Mesh:

Year:  1992        PMID: 1612036     DOI: 10.1055/s-2007-1010474

Source DB:  PubMed          Journal:  Endoscopy        ISSN: 0013-726X            Impact factor:   10.093


  3 in total

1.  Role of extracorporeal shock wave lithotripsy in hepato-biliary-pancreatic surgery.

Authors:  R L van der Hul; P W Plaisier; O T Terpstra; H A Bruining
Journal:  World J Surg       Date:  1993 Sep-Oct       Impact factor: 3.352

2.  Clinical comparison of extracorporeal piezoelectric lithotripsy (EPL) and intracorporeal electrohydraulic lithotripsy (EHL) in difficult bile duct stones. A prospective randomized trial.

Authors:  H E Adamek; A Buttmann; R Wessbecher; B Kohler; J F Riemann
Journal:  Dig Dis Sci       Date:  1995-06       Impact factor: 3.199

3.  Fast inverse distance weighting-based spatiotemporal interpolation: a web-based application of interpolating daily fine particulate matter PM2:5 in the contiguous U.S. using parallel programming and k-d tree.

Authors:  Lixin Li; Travis Losser; Charles Yorke; Reinhard Piltner
Journal:  Int J Environ Res Public Health       Date:  2014-09-03       Impact factor: 3.390

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.